Investor
Relations

Financial Information

Notes:

(a) The unaudited condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 30 September 2023 and the accompanying explanatory notes attached to this interim financial report.

(b) Based on 669,424,262 ordinary shares in issue as disclosed in Note B11.

Notes:

(a) The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 30 September 2023 and the accompanying explanatory notes attached to this interim financial report.

(b) Based on 669,424,262 ordinary shares in issue as disclosed in Note B11.

(c) Diluted earnings per share for the current financial period is calculated by dividing the profit for the financial period attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the financial period adjusted for the effects of dilutive potential ordinary shares as disclosed in Note B11.

Comparison with the preceding year corresponding quarter

The Group’s revenue recorded a decrease of 31% in the current quarter (“Q1FY24”) as compared to the preceding year corresponding quarter (“Q1FY23”) due to cautious capital expenditure spending from customers which foresee slowdown in semiconductor industry and deferment of delivery for the quarter under review due to slowdown in customers’ expansion pace.

The Group recorded forex gain of RM1.88m compared to Q1FY23 which incurred forex loss of RM1.93m.

R&D expenses have increased due to amortisation cost and more R&D resources are deployed in the research activities for new product development purposes.

As mentioned in last quarter, the recovery of semiconductor industry is on its way, despite being market and region specific.

The effort by our associate company, TMSS in business development and engineering engagement with customers has started to show results. The smartphone/tablet market has revived in China sales region. The Group foresees a positive impact to our financial result contributed by this region. We expect the trend to continue in the next few quarters with different degrees of growth.

Rest of the World sales region is expected to produce significantly better financial results in Q2FY24, as compared to Q1FY24.

Apart from our conventional products, the Group is expected to make progress in the medical electronics market too.

The Group strives to produce better financial results in FY2024, as compared to FY2023.